GenScript receives "Best CDMO " in the Korea Bioprocessing Excellence Awards 2021

25 June 2021 | Friday | News


GenScript receives the "Best Contract Development and Manufacturing Organization Award" on the Korea Bioprocessing Excellence Awards 2021 held on 24th June 2021. GenScript achieve the Best CDMO award for two years in a row.

GenScript receives the “Best Contract Development and Manufacturing Organization Award” on the Korea Bioprocessing Excellence Awards 2021

The Korea Bioprocessing Excellence Awards seeks to give recognition to exceptional bioprocessing experts, organizations and technologies that facilitate bio manufacturing excellence at enhanced speed, reduced cost and superior quality. GenScript is recognized to excellence CDMO services with strong technical capabilities and reasonable cost without compromising on the quality of service.

GenScript ProBio is the CDMO segment of GenScript Biotech Corporation, which is a world leading bio-pharmaceutical contract development and manufacturing organization (CDMO), with extensive services in gene synthesis, peptide synthesis, antibody development, protein expression and custom biological reagents, in addition to providing a one-stop biological drug R&D platform covering antibody drug discovery (hybridoma, phage display, full human and bispecific antibodies technologies), antibody engineering (antibody humanization, evaluation and optimization of drug compounds and affinity maturation), among others.

"We are honored to be recognized once again as a best CDMO by the Korea Bioprocessing Excellence Awards, which identifies the reputable partner for Korea customer's manufacturing needs. It is a great privilege to achieve the award for two years in a row and to attest to our solid position as a best CDMO service provider through our professional solutions and efficient processes to accelerate drug development," said Mr. Johnson Wang, President of GenScript APAC Division. " With a flexible partnership model based on industry, by pursuing innovation to meet customer's needs, such as next-generation antibodies, including dual antibodies and antibody-drug conjugates (ADCs), in the antibody field, we were able to provide quality of innovation and services to our customers continuously during the COVID-19 pandemic. In addition, it continues to demonstrate customer satisfaction and excellence in the field by continuing CDMO contracts and subsequent partnerships in Korea."

After the awards, he also showed strong confidence and added the following words. "We continuously strive to provide end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customer's satisfaction."

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close